Frontotemporal Dementia
FDA grants orphan drug designation to oral frontotemporal dementia treatment
The FDA has granted orphan drug designation to an oral, investigational, small-molecule therapeutic developed to treat frontotemporal dementia.
Overcoming Obstacles: Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease
This activity is supported by an independent educational grant from Otsuka and Lundbeck.
ADDF invests $5 million with Coya Therapeutics to develop, advance Alzheimer’s drugs
The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate development and advance drugs to prevent, treat and cure Alzheimer’s disease and related dementias.
FDA grants breakthrough designation to frontotemporal dementia treatment
The FDA has granted breakthrough therapy designation to latozinemab, an investigational therapeutic designed to block sortilin and elevate progranulin to treat frontotemporal dementia with a progranulin gene mutation.
Biotech firm to expand neuro therapy indications for frontotemporal dementia, Parkinson’s
A Houston-area biotech company will expand indications of its investigational and proprietary biologic combination therapy beyond amyotrophic lateral sclerosis to include frontotemporal dementia and Parkinson’s disease.
Frontotemporal dementia drug gets fast track designation from FDA
The FDA has cleared an investigational new drug application for AVB-101 to treat those with frontotemporal dementia with mutations in the progranulin gene, according to a release from the manufacturer.
Orphan drug designation sought for stem cell therapy to treat frontotemporal dementia
Therapeutic Solutions International has filed with the FDA to receive orphan drug designation for its JadiCell adult stem cell therapy for treatment of frontotemporal dementia.
No clinical benefit seen in trial of novel treatment for ALS, frontotemporal dementia
Topline results from a phase 1b/2a study evaluating an investigational therapy for C9orf72-associated ALS and frontotemporal dementia revealed no clinical benefit after 24 weeks of treatment compared with placebo.
Visual artistic creativity in FTD may be linked to disease onset, genetics, environment
The emergence of visual artistic creativity among those with frontotemporal dementia may be linked to early lesion-induced activation of the visual cortex and may depend on environment or genetics, according to research presented in JAMA Neurology.
Patients with frontotemporal dementia more likely to exhibit apathy, functional decline
People with behavioral variant frontotemporal dementia were more likely to exhibit apathy and functional decline, even in the mildest stage of dementia, compared with patients with Alzheimer’s disease, researchers recently reported.